These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 36217354)

  • 21. Outcomes of High-Grade Immune Checkpoint Inhibitor Hepatitis in Hospitalized and Nonhospitalized Patients.
    Li M; Wong D; Sack JS; Vogel AS; Hodi FS; Fong L; Lai JC; Zucker SD; Grover S
    Clin Gastroenterol Hepatol; 2024 Jul; 22(7):1444-1452.e4. PubMed ID: 38401693
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence, therapy and tumour response in patients with rheumatic immune-related adverse events following immune checkpoint inhibitor therapy: a single-centre analysis.
    Verspohl SH; Holderried T; Behning C; Brossart P; Schäfer VS
    Ther Adv Musculoskelet Dis; 2021; 13():1759720X211006963. PubMed ID: 33912248
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A case report of immune checkpoint inhibitor-related myositis and cholangitis induced by pembrolizumab.
    Yamano T; Hamakawa M; Akaike Y; Ishida T
    Clin Case Rep; 2024 Jul; 12(7):e9153. PubMed ID: 38962456
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer.
    Shao J; Wang C; Ren P; Jiang Y; Tian P; Li W
    Biosci Rep; 2020 May; 40(5):. PubMed ID: 32315071
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bilateral lung cancer showing various responses to immune checkpoint inhibitors: A case report.
    Kodama H; Ibe T; Inoue R; Shimada T; Ishii H; Hamamoto Y
    Cancer Rep (Hoboken); 2020 Oct; 3(5):e1272. PubMed ID: 32783372
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients.
    Purde MT; Niederer R; Wagner NB; Diem S; Berner F; Hasan Ali O; Hillmann D; Bergamin I; Joerger M; Risch M; Niederhauser C; Lenz TL; Früh M; Risch L; Semela D; Flatz L
    J Cancer Res Clin Oncol; 2022 Mar; 148(3):647-656. PubMed ID: 34874490
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system.
    Chen C; Wu B; Zhang C; Xu T
    Int Immunopharmacol; 2021 Jun; 95():107498. PubMed ID: 33725634
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acute Hepatitis E Infection during Chemotherapy for Lung Cancer: A Case Report.
    Okumura H; Miyamoto A; Suzuki F; Takaya H
    Chemotherapy; 2023; 68(3):155-159. PubMed ID: 37166305
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An autopsy case of lung adenocarcinoma with immune checkpoint inhibitor-induced pneumonia and fulminant myocarditis following pembrolizumab administration: a case report.
    Hashimoto T; Takahashi K; Ito K; Iwade K; Torii A; Sugihara M; Kondo H; Hara T
    Int Cancer Conf J; 2024 Jul; 13(3):218-222. PubMed ID: 38962041
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents.
    Suzman DL; Pelosof L; Rosenberg A; Avigan MI
    Liver Int; 2018 Jun; 38(6):976-987. PubMed ID: 29603856
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition.
    Naqash AR; Appah E; Yang LV; Muzaffar M; Marie MA; Mccallen JD; Macherla S; Liles D; Walker PR
    J Immunother Cancer; 2019 Jul; 7(1):169. PubMed ID: 31277704
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Toxicity spectrum of immunotherapy in advanced lung cancer: A safety analysis from clinical trials and a pharmacovigilance system.
    Yan YD; Zhao Y; Zhang C; Fu J; Su YJ; Cui XL; Ma EL; Liu BL; Gu ZC; Lin HW
    EClinicalMedicine; 2022 Aug; 50():101535. PubMed ID: 35812997
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.
    Zheng Y; Kim R; Yu T; Gayle JA; Wassel CL; Dreyfus J; Phatak H; George S
    Oncologist; 2021 Nov; 26(11):e2002-e2012. PubMed ID: 34327774
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety of Immune Checkpoint Inhibitors in Patients with Cancer and Hepatitis C Virus Infection.
    Alkrekshi A; Tamaskar I
    Oncologist; 2021 May; 26(5):e827-e830. PubMed ID: 33655663
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Renal Immune-related Adverse Event of Pembrolizumab Masked by Pemetrexed.
    Nagase K; Murai Y; Yokoyama-Kokuryo W; Nagasaka T; Sato Y; Watanabe T; Ito Y; Nagase F; Fujita Y
    Intern Med; 2024 Jan; 63(2):265-270. PubMed ID: 37258166
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chemotherapy-induced nausea and vomiting (CINV) with carboplatin plus pemetrexed or carboplatin plus paclitaxel in patients with lung cancer: a propensity score-matched analysis.
    Hayashi T; Shimokawa M; Matsuo K; Iihara H; Kawada K; Nakano T; Egawa T
    BMC Cancer; 2021 Jan; 21(1):74. PubMed ID: 33451299
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current Status of Immune Checkpoint Inhibitor Immunotherapy for Lung Cancer.
    Xiong W; Zhao Y; Du H; Guo X
    Front Oncol; 2021; 11():704336. PubMed ID: 34490104
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
    Godwin JL; Jaggi S; Sirisena I; Sharda P; Rao AD; Mehra R; Veloski C
    J Immunother Cancer; 2017; 5():40. PubMed ID: 28515940
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment Rationale and Design for APPLE (WJOG11218L): A Multicenter, Open-Label, Randomized Phase 3 Study of Atezolizumab and Platinum/Pemetrexed With or Without Bevacizumab for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.
    Shiraishi Y; Kishimoto J; Tanaka K; Sugawara S; Daga H; Hirano K; Azuma K; Hataji O; Hayashi H; Tachihara M; Mitsudomi T; Seto T; Nakagawa K; Yamamoto N; Okamoto I
    Clin Lung Cancer; 2020 Sep; 21(5):472-476. PubMed ID: 32381420
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discontinuation of Immune Checkpoint Inhibitor and Survival in Patients With Non-small-cell Lung Cancer Without a Driver Gene Mutation.
    Hattori S; Okauchi S; Sasatani Y; Ohara G; Miyazaki K; Sato S; Kodama T; Shiozawa T; Satoh H; Hizawa N
    Anticancer Res; 2022 Sep; 42(9):4589-4595. PubMed ID: 36039463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.